We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers

By MedImaging International staff writers
Posted on 08 Jan 2024
Image: Researchers will study targeted radiation for treatment-resistant cancers (Photo courtesy of 123RF)
Image: Researchers will study targeted radiation for treatment-resistant cancers (Photo courtesy of 123RF)

Alpha-particle emitter radiopharmaceutical therapy (alpha-emitter RPT) is an emerging cancer treatment that has shown considerable success in targeting widespread, resistant cancer cells by directly delivering potent radiation. Administered intravenously, this therapy involves attaching radioactive atoms, which emit alpha-particles or helium nuclei, to molecules specifically designed to bind with cancer cells scattered throughout the body. This targeted approach allows the alpha-particles to inflict substantial DNA damage to the cancer cells, effectively destroying them, while also minimizing harm to the surrounding healthy tissues and mitigating some of the severe side effects typically associated with radiation and chemotherapy.

In recent years, the FDA has approved several agents utilizing this method to deliver radiation therapies aimed at treatment-resistant cancers, sparking an increased demand to refine these treatments and explore new specific radiation therapies. Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) who have previously established the efficacy of this therapy in managing various metastatic cancers that are unresponsive to standard treatments, are now set to further enhance the alpha-emitter RPT with a USD 15 million grant from the National Cancer Institute. Their focus will be on fine-tuning the therapy and customizing its use, including developing sophisticated imaging techniques and understanding the radiation's distribution in tissues to personalize treatment for each patient. The research team plans to delve into the mathematical and physics-based aspects of alpha-emitter RPT to address these challenges effectively.

“The study of these types of radiation treatments is a very active field that is also very niche,” said George Sgouros, Ph.D., director of the radiological physics division and professor of radiology and radiological science at the Johns Hopkins University School of Medicine. “It is a unique area of study because a multidisciplinary team is needed to fully optimize such therapies, everything from physics, radiochemistry, biology and pharmacokinetics impacts this treatment approach.”

Related Links:
Johns Hopkins Medicine

Silver Member
X-Ray QA Meter
T3 AD Pro
Digital Radiographic System
OMNERA 300M
Ultrasound Imaging System
P12 Elite
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.